Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Interferon-beta dose and efficacy: the OPTIMS study.

L Durelli1, A Oggero, E Verdun

  • 1Department of Neurosciences, University of Turin, Italy.

Neurological Sciences : Official Journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology
|October 18, 2001
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Serum Neurofilaments are a reliable biomarker to early detect PML in Multiple Sclerosis patients.

Multiple sclerosis and related disorders·2023
Same author

[Open radiofrequency liver resection: technical details].

Minerva chirurgica·2006
Same author

Venoruton vs Daflon: evaluation of effects on quality of life in chronic venous insufficiency.

Angiology·2006
Same author

Every-other-day interferon beta-1b versus once-weekly interferon beta-1a for multiple sclerosis (INCOMIN Trial) II: analysis of MRI responses to treatment and correlation with Nab.

Multiple sclerosis (Houndmills, Basingstoke, England)·2006
Same author

Venous ulcers: microcirculatory improvement and faster healing with local use of Pycnogenol.

Angiology·2005
Same author

A plaster combining diclofenac and heparin: microcirculatory evaluation in 2 models of high-perfusion microangiopathy.

Angiology·2005
Same journal

Brain-muscle axis regulation of neuroinflammation and sarcopenia in Parkinson's disease: the bridging role of lactylation.

Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology·2026
Same journal

Early and severe masticatory muscle involvement in SOD1-ALS: a case report with biomarker-clinical dissociation.

Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology·2026
Same journal

Early multimodal predictors of good neurological outcome in comatose patients after cardiac arrest: a prospective single-center cohort study.

Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology·2026
Same journal

Telemedicine for headache disorders in real-world practice: from patient experience to health system impact.

Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology·2026
Same journal

Topography and functional connectivity analysis of heart surgery-associated brain lesions: a literature review.

Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology·2026
Same journal

Limb apraxia in Parkinson's disease and atypical parkinsonian syndromes: a systematic review.

Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology·2026
See all related articles

Higher doses of interferon beta (IFN-beta) may improve treatment outcomes for relapsing-remitting multiple sclerosis (MS) patients who do not respond to standard therapy. This study investigates optimal dosing for improved clinical efficacy.

Area of Science:

  • Neuroimmunology
  • Pharmacology
  • Clinical Neurology

Background:

  • Interferon beta (IFN-beta) is a disease-modifying therapy for relapsing-remitting multiple sclerosis (MS).
  • A significant proportion of MS patients exhibit inadequate response to standard IFN-beta doses.
  • Evidence suggests a dose-response relationship for IFN-beta in reducing MS exacerbations and MRI-detected disease activity.

Purpose of the Study:

  • To compare the efficacy of two different doses of interferon beta-1b in patients with relapsing-remitting MS.
  • To evaluate the impact of dose escalation on clinical and MRI-based disease markers in non-responders.

Main Methods:

  • The study design for the multicenter "Optimization of Interferon for MS" (OPTIMS) trial is presented.
  • The trial will compare standard versus higher doses of IFN-beta-1b.

Related Experiment Videos

  • Patient response will be assessed through clinical evaluation and magnetic resonance imaging (MRI).

    • Main Results:

    • A 30% treatment failure rate was observed with 8 MIU IFN-beta in a prior observation.
    • Escalation to 12 MIU IFN-beta in non-responders showed improvement in clinical signs of disease activity.

    Conclusions:

    • Higher doses of IFN-beta-1b may offer a viable strategy for managing MS in patients with suboptimal response to standard treatment.
    • The OPTIMS study aims to provide robust data on dose optimization for IFN-beta therapy in MS.